O’Brien, Kieran S.
,
Arzika, Ahmed M.
Amza, Abdou
Maliki, Ramatou
Ousmane, Sani
Kadri, Boubacar
Nassirou, Beido
Mankara, Alio Karamba
Harouna, Abdoul Naser
Colby, Emily
Lebas, Elodie
Liu, Zijun
Le, Victoria
Nguyen, William
Keenan, Jeremy D.
Oldenburg, Catherine E.
Porco, Travis C.
Doan, Thuy
Arnold, Benjamin F.
Lietman, Thomas M.
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV-002454, OPP1210548)
Peierls Foundation
That Man May See
Research to Prevent Blindness
Article History
Received: 4 March 2021
Accepted: 13 April 2021
First Online: 29 April 2021
Declarations
:
: The University of California San Francisco Institutional Review Board has given ethical approval for the trial and will review the trial annually (19–28287). The Comité National Éthique pour la Recherche en Santé in Niger granted ethical approval before study activities began (DELIBERATION No. 041/2020/CNERS).Verbal consent will be obtained from the head of household for participation in the census and from guardians for treatment administration. For children aged 30 to 42 days old, written consent will be obtained via caregiver thumbprint, as requested by the UCSF IRB given the possible risk of infantile hypertrophic pyloric stenosis with macrolides in this age group [CitationRef removed]. Verbal consent will be obtained from regional, district and community leaders before recruiting any participants into the study. For specimen collections, additional written informed consent will be obtained from participants and/or caregivers before data collection. There is no financial cost to the participant and there is no reimbursement for overall participation in this study.
: Not applicable.
: None.